{
    "clinical_study": {
        "@rank": "40069", 
        "arm_group": [
            {
                "arm_group_label": "Cultured mesenchymal stem cell transplantation", 
                "arm_group_type": "Experimental", 
                "description": "Patients with Type 2 Diabetes mellitus on full doses of Vildagliptin+Pioglitazone+Metformin and requiring Insulin at dose of >0.4unit/Kg for blood glucose control."
            }, 
            {
                "arm_group_label": "Control", 
                "arm_group_type": "Sham Comparator", 
                "description": "vildagliptin+metformin+pioglitazone and on Insulin >0.4unit/Kg who will act as active control.They will receive injectable placebo at Day 1 in addition to above and will be followed up for 6 months.Follow up investigation and Insulin dose titration will be similar to Group 1"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to improve the blood glucose level in type 2 diabetic patients."
        }, 
        "brief_title": "Cultured Mesenchymal Stem Cell Transplantation in T2DM", 
        "completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Type 2 Diabetes Mellitus", 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2"
            ]
        }, 
        "detailed_description": {
            "textblock": "We hypothesize that Autologous bone marrow derived mesenchymal stem cells which would be\n      expanded into culture and their subsequent transplant into the pancreas of patients with\n      T2DM, aged 30 - 70 years with triple oral hypoglycemic agent failure and on insulin(>0.4 U/\n      kg body weight/day) will lead to abolition or reduction of insulin requirement by more than\n      or equal to 50% in these patients over a period of 6 months. It is assumed that cultured\n      mesenchymal stem cell in these patients leads to increased angiogenesis, secretion of\n      various cytokines and upregulation of pancreatic transcription factors and Vascular\n      endothelial growth factor(VEGF) and creates a micro-environment which supports beta\n      cell/resident stem cell activation and survival."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        Patients with type 2 diabetes mellitus between 30 and 70 years of age.\n\n          -  Failure to triple oral hypoglycemic agent and on stable doses of insulin for at least\n             3 months.\n\n          -  On vildagliptin,pioglitazone and metformin for at least 3 months along with Insulin\n             to maintain euglycemia.\n\n          -  HbA1c < 7.5%.\n\n          -  Insulin requirement \u22650.4 IU/kg/d.\n\n          -  GAD antibody negative status.\n\n        Exclusion Criteria:\n\n          -  Patients with type 1 diabetes mellitus or secondary diabetes.\n\n          -  Patients with serum creatinine > 1.5 mg/dl.\n\n          -  Abnormal liver function tests (defined as value of transaminases > 3 times the upper\n             value of normal or serum bilirubin higher than normal for the reference value for the\n             laboratory).\n\n          -  History of cholecystitis/ cholelithiasis/ cholecystectomy\n\n          -  Seropositivity for HIV, HBsAg and hepatitis C virus (HCV).\n\n          -  History of myocardial infarction or unstable angina in the previous 3 months.\n\n          -  History of malignancy\n\n          -  Patients with active infections."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "30 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 30, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01759823", 
            "org_study_id": "Mesenchymal stem cell in T2DM"
        }, 
        "intervention": [
            {
                "arm_group_label": "Cultured mesenchymal stem cell transplantation", 
                "description": "20 - 30 ml of bone marrow will be aspirated and layered on density gradient medium (Ficoll - hypaque ) and stem cells will be separated. Separated mono nucleated cells will be dissolved in minimum essential medium and inoculated in culturing flask and mesenchymal will be allowed to adhere to culturing flask and mesenchymal stem cell will be injected into superior pancreatic duodenal artery . Patients will be urged to monitor and document blood glucose readings for next 6 months. Glucagon stimulated C - peptide,hyperinsulinemic euglycemic clamp for assessment of insulin resistance, plasma Insulin, Homeostasis Model of Assessment - Insulin Resistance and Beta cell function ,HbA1c, lipid profile and biochemistry will be done at baseline and 6 months .", 
                "intervention_name": "Cultured mesenchymal stem cell transplantation", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "Control", 
                "description": "5 ml of bone marrow will be aspirated and 3 mL of Vitamin B complex will be injected through transfemoral route into superior pancreatico-duodenal artery.  Patients will be urged to monitor and document blood glucose readings for next 6 months. Glucagon stimulated C - peptide,hyperinsulinemic euglycemic clamp for assessment of insulin resistance, plasma Insulin, Homeostasis Model of Assessment - Insulin Resistance and Beta cell function ,HbA1c, lipid profile and biochemistry will be done at baseline and 6 months .", 
                "intervention_name": "control", 
                "intervention_type": "Other"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "January 2, 2013", 
        "location": {
            "contact": {
                "email": "bhansali.o4@gmail.com", 
                "last_name": "Pinaki Dutta, MBBS,MD,DM", 
                "phone": "9463001233"
            }, 
            "facility": {
                "address": {
                    "city": "Chandigarh", 
                    "country": "India", 
                    "state": "UT", 
                    "zip": "160012"
                }, 
                "name": "Postgraduate Institute of Medical Education and Research"
            }, 
            "investigator": {
                "last_name": "Pinaki Dutta", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "India"
        }, 
        "number_of_arms": "2", 
        "official_title": "Efficacy and Safety of Autologous Bone Marrow Derived Mesenchymal Stem Cell Transplantation in Patients With Type 2 Diabetes Mellitus", 
        "overall_contact": {
            "email": "bhansali.o4@gmail.com", 
            "last_name": "Pinaki Dutta, MBBS, MD,DM", 
            "phone": "9463001233"
        }, 
        "overall_official": [
            {
                "affiliation": "Post Graduate Institute Of Medical Education And Research, Chandigarh", 
                "last_name": "Pinaki Dutta", 
                "role": "Study Chair"
            }, 
            {
                "affiliation": "Postgraduate Institute of Medical Education and Research, Chandigarh", 
                "last_name": "V Jha", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Postgraduate Institute of Medical Education and Research  , Chandigarh", 
                "last_name": "Neelam Marwaha", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "India: Indian Council of Medical Research", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2/Phase 3", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Reduction of insulin requirement by \u2265 50% by the end of 6 months of autologous bone marrow mesenchymal stem cell transplantation and Improvement in Glucagon stimulated C - peptide levels and insulin sensitivity by HYPERINSULINEMIC EUGLYCEMIC CLAMP", 
            "safety_issue": "No", 
            "time_frame": "6 months"
        }, 
        "reference": {
            "PMID": "19686048", 
            "citation": "Bhansali A, Upreti V, Khandelwal N, Marwaha N, Gupta V, Sachdeva N, Sharma RR, Saluja K, Dutta P, Walia R, Minz R, Bhadada S, Das S, Ramakrishnan S. Efficacy of autologous bone marrow-derived stem cell transplantation in patients with type 2 diabetes mellitus. Stem Cells Dev. 2009 Dec;18(10):1407-16."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01759823"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Postgraduate Institute of Medical Education and Research", 
            "investigator_full_name": "pinaki dutta", 
            "investigator_title": "Assistant Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Postgraduate Institute of Medical Education and Research", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Postgraduate Institute of Medical Education and Research", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2013"
    }
}